Sign up to emails

Subscribe to Baillie Gifford emails for monthly updates directly to your inbox.

Print article

Denali Therapeutics: rising to the challenge of brain disease

Claire Shaw, Portfolio Director

Key Points

  • Neurodegenerative diseases, including Alzheimer’s and Parkinson’s, are set to affect more people as life expectancies increase
  • Denali Therapeutics is developing a range of treatments to tackle brain diseases
  • The US firm is developing a new generation of medicines that can effectively treat neurodegenerative diseases

All investment strategies have the potential for profit and loss, capital is at risk.

Over the last decade, a large number of big pharmaceutical companies have quit neuroscience.

It’s a puzzling phenomenon when you consider that one in three people born today will develop dementia. Why leave such an important field when the unmet need is so great?

The answer is the huge failure rate in developing treatments for neurodegenerative disease. The disorders affect nerve cells in a patient’s brain and nervous system, damaging or destroying them. This can result in the sufferer losing coordination, mobility, strength, sensation and the ability to speak and breathe. Ultimately, death often follows. Despite huge efforts, many of these conditions remain incurable.

Take Alzheimer’s, for example – one study found that over 99 per cent of drug candidates that made it to clinical trials were found to be no better than a placebo.

Big pharma has spent billions yet has made little progress.

Despite all this, Denali Therapeutics, a nimble San Francisco start-up, has dedicated itself to tackling the problem. And for Ryan Watts, the business’s co-founder and CEO, it’s a deeply personal mission.

“I think the first, probably most compelling experience, is that my wife’s family has a history of Alzheimer’s disease,” he explains. “And I remember her grandfather developing Alzheimer’s disease. I thought, ‘maybe there’s an area I should start focusing on.’

“But the driving force for me [was] seeing my own mother start to develop dementia. I know my genetic risk. I know her genetic risk. It’s imputed from mine.”

Click here to download transcript

LISTEN: Denali Therapeutics’s CEO Ryan Watts tells Tom Slater why he believes it can succeed where big pharma has failed by creating effective drugs for neurodegenerative diseases.

The blood-brain barrier

Developing brain drugs is notoriously difficult for three reasons:

    • Our understanding of the genetic and molecular basis of neurodegenerative diseases is incomplete.
    • It’s hard to test if a drug is working because you can’t biopsy the brain in the way you might biopsy a tumour.
    • Once a drug has been developed, it’s tricky to get it into the brain due to a mechanism called the blood-brain barrier. It keeps out harmful chemicals but unfortunately limits the uptake of medicine too.


This third point has been a particular challenge. Natural active transport systems exist to carry some large molecules through, such as sugar or iron. One of Denali’s key achievements is having found a way to harness these to create a ‘transport vehicle technology’ that effectively sneaks through molecules that would otherwise be blocked.

Denali believes it can succeed where others have failed. It’s asking the right questions, solving technical challenges and taking bigger risks than its competitors. But, counterintuitively, what’s also essential to its progress is that it’s prepared for failure.


Multiple molecules

Dementia isn’t the company’s only focus – it’s also attempting to tackle Parkinson’s and the motor neuron disease amyotrophic lateral sclerosis (ALS), among other disorders. This broad remit distinguishes it from the narrower approach biotech start-ups traditionally take.

“You can’t be focused on a single idea or hypothesis,” explains Watts. “You can’t found a company based on one molecule. The chances of that succeeding are extremely low. We knew at the beginning that there were two things we needed. We needed a pipeline, which is basically multiple medicines. And we needed a platform that, if successful, would open up all of the nervous system, not just neurodegenerative diseases.”

Denali has seven medicines in clinical development. Three are in the final stages before being submitted for approval. Part of being able to follow the science and take forward multiple potential drugs at once is having a big balance sheet.

“It allows you to fail, to iterate and to accelerate,” says Watts. “You need the capital in order to get data really quickly and understand the direction.  

“We have had at least a dozen programmes that we stopped developing. Any one of those programmes would be a single biotech company. But because we had that capital, it allowed us to really invest in the underlying science and the platform.”


Aiming for achievement

Denali’s company culture also comes into the equation. Its employees recognise the firm’s purpose is more important than the organisation itself. That diminishes the impact of setbacks while making successes even more meaningful.

Watts highlights a recent triumph against Hunter syndrome, a rare and harmful inherited disorder in which the body does not properly break down sugar molecules, causing damage to the brain. The firm developed an enzyme replacement therapy that’s capable of crossing the blood-brain barrier.

“We have gotten to know several of the families that have children with Hunter syndrome,” he says. “Some will develop very normally. And by ages three, four or five, learn to walk and talk and then they’ll start to lose their ability. It’s just unbelievably devastating.

“Fast-forward, we get our medicine into the clinic. We get our very first data. [The chief medical officer] called me, and she says, Ryan, four out of the five patients have completely normal levels of the substrate in the brain. And it was unbelievable.”

Denali hopes to replicate this achievement. So, what does the world look like if it succeeds? For Watts, it’s about creating a future where people live longer and can die with dignity.

For now, its clinical data is encouraging. And if its drugs are approved, they have the potential to advance medical science, save people’s lives and propel the company along the path to long-term growth.

Risk factors

The views expressed should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

This communication was produced and approved in March 2023 and has not been updated subsequently. It represents views held at the time of writing and may not reflect current thinking.

This communication contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act (‘FinSA’) and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated.

The images used in this communication are for illustrative purposes only.


Important information

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Financial intermediaries

This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.


Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018. Baillie Gifford Investment Management (Europe) Limited is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. Baillie Gifford Investment Management (Europe) Limited is also authorised in accordance with Regulation 7 of the AIFM Regulations, to provide management of portfolios of investments, including Individual Portfolio Management (‘IPM’) and Non-Core Services. Baillie Gifford Investment Management (Europe) Limited has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. Through passporting it has established Baillie Gifford Investment Management (Europe) Limited (Frankfurt Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in Germany. Similarly, it has established Baillie Gifford Investment Management (Europe) Limited (Amsterdam Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in The Netherlands. Baillie Gifford Investment Management (Europe) Limited also has a representative office in Zurich, Switzerland pursuant to Art. 58 of the Federal Act on Financial Institutions (‘FinIA’). The representative office is authorised by the Swiss Financial Market Supervisory Authority (FINMA). The representative office does not constitute a branch and therefore does not have authority to commit Baillie Gifford Investment Management (Europe) Limited. Baillie Gifford Investment Management (Europe) Limited is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.


Baillie Gifford Investment Management (Shanghai) Limited
柏基投资管理(上海)有限公司(‘BGIMS’) is wholly owned by Baillie Gifford Overseas Limited and may provide investment research to the Baillie Gifford Group pursuant to applicable laws.  BGIMS is incorporated in Shanghai in the People’s Republic of China (‘PRC’) as a wholly foreign-owned limited liability company with a unified social credit code of 91310000MA1FL6KQ30. BGIMS is a registered Private Fund Manager with the Asset Management Association of China (‘AMAC’) and manages private security investment fund in the PRC, with a registration code of P1071226.

Baillie Gifford Overseas Investment Fund Management (Shanghai) Limited
柏基海外投资基金管理(上海)有限公司(‘BGQS’) is a wholly owned subsidiary of BGIMS incorporated in Shanghai as a limited liability company with its unified social credit code of 91310000MA1FL7JFXQ. BGQS is a registered Private Fund Manager with AMAC with a registration code of P1071708. BGQS has been approved by Shanghai Municipal Financial Regulatory Bureau for the Qualified Domestic Limited Partners (QDLP) Pilot Program, under which it may raise funds from PRC investors for making overseas investments.

Hong Kong

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and a Type 2 license from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713–2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong. Telephone +852 3756 5700.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.


Mitsubishi UFJ Baillie Gifford Asset Management Limited (‘MUBGAM’) is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.


Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a ‘wholesale client’ within the meaning of section 761G of the Corporations Act 2001 (Cth) (‘Corporations Act’). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this material be made available to a ‘retail client’ within the meaning of section 761G of the Corporations Act.

This material contains general information only. It does not take into account any person’s objectives, financial situation or needs.

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission (‘OSC’). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited (‘BGE’) relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.


Baillie Gifford Overseas is not licensed under Israel’s Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755–1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.


Claire Shaw

Portfolio Director

Claire Shaw is a portfolio director and plays a prominent role in servicing Scottish Mortgage’s UK shareholder base. Before joining in 2019, she spent over a decade as a fund manager with a focus on managing European equity portfolios for a global client base. With a background in analysing companies and communicating investment ideas, Claire is also responsible for creating engaging content that makes the Scottish Mortgage portfolio accessible to all its shareholders. Beyond that, she works closely with the managers, meeting with portfolio companies and conducting in-depth portfolio discussions with shareholders.

Back to top